5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione and its salts for use in the treatment of mitochondrial diseases
AssigneeMinoryx Therapeutics S.L.
InventorsMarc Martinell Pedemonte, Maria Pilar Pizcueta Lalanza, Laura Pilar Rodríguez Pascau
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to a method of treating or preventing mitochondrial diseases by administering 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione or a salt thereof to a subject in need thereof. The disclosure also relates to 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione for use in a pharmaceutical composition or in the manufacture of a medicament for the treatment or prevention of a mitochondrial disease.
Claims18
A method of treating a mitochondrial disease, comprising administering to a subject in need thereof a compound of formula (1)
- or a pharmaceutically acceptable salt thereof, in an amount effective to treat said mitochondrial disease, wherein said mitochondrial disease is selected from the group consisting of Rett syndrome, Leigh's syndrome, autosomal dominant optic atrophy (ADOA), Complex I deficiency, Leber's hereditary optic neuropathy (LHON), mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS), and NDUFS1 deficiency.
Dependencies are inferred from the claim text.